trending Market Intelligence /marketintelligence/en/news-insights/trending/6um9jh0orhbekupfxyfj-a2 content esgSubNav
In This List

Pharmaxis manufacturing facility for asthma drug gets US FDA approval

Blog

Insight Weekly: US stock market downturn; Chinese bank earnings; Europe's big tech bills

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022


Pharmaxis manufacturing facility for asthma drug gets US FDA approval

Pharmaxis Ltd. said the U.S. Food and Drug Administration approved its Sydney-based manufacturing facility for the production of Aridol, an asthma diagnostic product.

In 2011, the FDA approved Aridol to help doctors diagnose and manage asthma in patients aged 6 years and older. The drug was withdrawn from the U.S. market as part of the company's corporate restructuring in 2013.

The Australian company will initiate the U.S. relaunch of Aridol in the fourth quarter through Methapharm Inc., its exclusive distribution partner.

The manufacturing facility now produces Aridol for markets in Europe, Australia and South Korea. It is also where Pharmaxis manufactures Bronchitol, an approved treatment for certain patients with cystic fibrosis developed to help clear mucus from their lungs.